MADRID, Spain—A tailored treatment strategy based on the ABC-AF stroke and bleeding risk scores is no better than usual care for patients with atrial fibrillation (AF) and a low-to-moderate risk of ...

Patients recently diagnosed with cancer show an increased risk for major bleeding after myocardial infarction, with the risk ...

Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...

In patients with AF, abelacimab, compared with rivaroxaban, is associated with decreased bleeding across multiple bleeding risk categories. Abelacimab is associated with reduced bleeding compared with ...

Abelacimab shows promise in reducing bleeding risks compared to rivaroxaban, offering a safer anticoagulation option for atrial fibrillation patients. Factor XI inhibition could optimize ...

Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality among hospitalised medical patients. Ongoing efforts to refine risk assessment and optimise prophylactic strategies ...

Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of ...

Please provide your email address to receive an email when new articles are posted on . A systematic review and meta-analysis of nine trials comparing non-vitamin K oral anticoagulants with low-dose ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...

A major international analysis of 2,313 patients, median age 71, found that giving an IV clot-busting drug before mechanical clot removal modestly increases brain-bleeding risk compared with ...